BACE1 inhibitor drugs in clinical trials for Alzheimer's disease - PubMed (original) (raw)

Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.

Alić I, Goh PA, Murray A, Portelius E, Gkanatsiou E, Gough G, Mok KY, Koschut D, Brunmeir R, Yeap YJ, O'Brien NL, Groet J, Shao X, Havlicek S, Dunn NR, Kvartsberg H, Brinkmalm G, Hithersay R, Startin C, Hamburg S, Phillips M, Pervushin K, Turmaine M, Wallon D, Rovelet-Lecrux A, Soininen H, Volpi E, Martin JE, Foo JN, Becker DL, Rostagno A, Ghiso J, Krsnik Ž, Šimić G, Kostović I, Mitrečić D; LonDownS Consortium; Francis PT, Blennow K, Strydom A, Hardy J, Zetterberg H, Nižetić D. Alić I, et al. Mol Psychiatry. 2021 Oct;26(10):5766-5788. doi: 10.1038/s41380-020-0806-5. Epub 2020 Jul 10. Mol Psychiatry. 2021. PMID: 32647257 Free PMC article.